Together with others, DTU researchers have confirmed that a variation in a gene called ATM could help to explain why some people have a better response to a first-line drug for type 2 diabetes called metformin.
This study, which confirms work published previously in Nature Genetics, has examined an additional population of over 1000 people taking metformin in the UK and the Netherlands.
In the future, doctors could use results like these to help select the most appropriate therapy for an individual based on their predicted response to the treatment.
The paper was published in Diabetologia. To read the full paper, click below: